NovaBiotics’ core technology harnesses the beneficial properties of these natural infection-fighting agents and has created a totally novel class of potent, synthetic peptides and aminothiols as interventions or prevention in a range of fungal, bacterial and polymicrobial infections.
NovaBiotics’ drug candidates have been designed to meet the urgent need for safer, more effective antimicrobials and address the various and well described shortcomings of conventional anti-infective therapies. Importantly, the mode of action of NovaBiotics' peptides is such that they kill rather than merely inhibit pathogens. This minimises if not negates the likelihood of acquired or transmitted pathogen resistance developing in micro-organisms which have been exposed to NovaBiotics drug candidates.
Rapid Development of Products to Clinic
A combination of intelligent drug design and the development/implementation of best in class, clinically de-risking model systems - not higher risk screening strategies - has streamlined Novabiotics discovery process such that product candidates have been delivered to clinic less than 5 years from patent priority dates.
NovaBiotics technological and commercial approach has already been validated through successful development to phase II/III and securing commercial partnership agreements for its two lead compounds; Novexatin and Lynovex (oral).